Solid Biosciences Receives FDA Rare Pediatric Disease Designation For Sgt-212 Dual Route Of Administration Gene Therapy

Reuters
2025.12.01 13:31
Dec 1 (Reuters) - Solid Biosciences Inc (SLDB.O) : * SOLID BIOSCIENCES RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR SGT-212 DUAL ROUTE OF ADMINISTRATION GENE THERAPY FOR FRIEDREICH’S ATAXIA Source text: Further company coverage: (SLDB.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer